NAD⁺ Injections and “NAD Boosters”

Public Health Risks, Adverse Effects, and Regulatory Implications in the Context of Rapid Consumer Adoption

Abstract

Background:
Nicotinamide adenine dinucleotide (NAD⁺) is an essential endogenous coenzyme central to cellular energy metabolism, redox balance, DNA repair, immune regulation, and stress-response signalling [1–3]. Age-associated alterations in NAD⁺ biology have stimulated scientific interest and preclinical research. In parallel, NAD⁺ injections/infusions and oral “NAD boosters” (primarily nicotinamide riboside [NR] and nicotinamide mononucleotide [NMN]) have rapidly expanded in wellness markets, often promoted for anti-aging, “detoxification,” cognitive enhancement, and disease prevention. Population exposure has increased ahead of outcomes-based clinical evidence and long-term safety evaluation.

Objective:
To provide a policy-relevant, evidence-based analysis of the public health implications of NAD⁺ injections and NAD-boosting supplements, focusing on adverse effects, long-term uncertainty, product quality risks, misinformation-driven behavioural harm, and downstream burden on health systems.

Methods:
A narrative public health and regulatory review was conducted, integrating peer-reviewed clinical trials and critical reviews of NAD-boosting interventions, mechanistic literature relevant to long-term risk, and regulatory/public health evidence on supplement adulteration, pharmacovigilance limitations, and health misinformation.

Results:
Human trials confirm that NAD-boosting interventions are pharmacologically active and can cause adverse effects, while benefits remain largely limited to surrogate biomarkers rather than patient-important outcomes [6–11]. Long-term safety (including cancer and cardiovascular outcomes) is not established. Evidence from supplement oversight demonstrates recurring problems with adulteration and quality failures [14–17] and weak post-market surveillance [18,19]. Misinformation amplifies adoption and may displace evidence-based prevention, contributing to avoidable system-level costs [21,22].

Conclusion:
Current consumer diffusion of NAD⁺ injections and NAD-boosting supplements represents a public health risk profile: unproven benefit on meaningful outcomes, documented short-term adverse effects, profound long-term uncertainty, variable product quality, and governance gaps. Precautionary policy, strengthened surveillance, and evidence-led communication are warranted.